시장보고서
상품코드
1630682

말단비대증 치료 시장 규모, 점유율, 성장 분석 : 질환 유형별, 진단 유형별, 치료 유형별, 지역별 - 산업 예측)2025-2032년)

Acromegaly Treatment Market Size, Share, Growth Analysis, By Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), By Diagnosis Type (Medical Imaging, Medical Laboratory Test), By Treatment Type, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 말단비대증 치료 시장 규모는 2023년에 14억 달러로 평가되며, 2024년 14억 9,000만 달러에서 2032년에는 23억 9,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 6.1%로 성장할 전망입니다.

말단비대증 치료제 시장은 발병률 증가와 혁신적인 치료법에 대한 수요 증가로 인해 강력한 성장이 예상됩니다. R&D 투자가 급증하면서 제약사들은 새로운 제형과 투여 방법의 개발에 집중하고 있습니다. 유전성 질환의 확산과 라이프스타일의 변화는 특히 호르몬 장애가 보편화됨에 따라 이러한 수요를 더욱 촉진할 것으로 예상됩니다. 특히 새로운 성장호르몬 수용체 길항제 및 소마토스타틴 유사 약물의 FDA 승인 등 강력한 제약 파이프라인이 시장 잠재력을 더욱 높일 것으로 예상됩니다. 방사선 수술과 같은 검출 방법의 기술적 발전은 치료 효과를 높이고 부작용을 줄일 수 있습니다. 또한 희귀질환에 대한 정부의 지원 정책과 프로그램은 향후 수년간 시장 확대에 기여할 것으로 보입니다.

목차

서론

  • 조사의 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차 데이터와 1차 데이터 방법
  • 시장 규모 예측
  • 시장의 전제조건과 제한

개요

  • 세계 시장 전망
  • 공급과 수요의 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장 에코시스템
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석

말단비대증 치료 시장 규모 : 질환 유형별

  • 시장 개요
  • 이소성 말단비대증
  • 위성 말단비대증

말단비대증 치료 시장 규모 : 진단 유형별

  • 시장 개요
  • 의료 영상
  • 임상 검사

말단비대증 치료 시장 규모 : 치료 유형별

  • 시장 개요
  • 수술
  • 약물 요법
  • 방사선 치료

말단비대증 치료 시장 규모

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카 지역
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 시장의 최근 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업의 기업 개요
    • 회사 개요
    • 제품 포트폴리오 분석
    • 부문별 점유율 분석
    • 매출의 전년대비 비교(2022-2024년)

주요 기업 개요

  • Novartis AG(Switzerland)
  • Ipsen Pharma(France)
  • Pfizer Inc.(USA)
  • Crinetics Pharmaceuticals, Inc.(USA)
  • Strongbridge Biopharma plc(Ireland)
  • Ionis Pharmaceuticals, Inc.(USA)
  • Merck & Co., Inc.(USA)
  • AbbVie Inc.(USA)
  • Eli Lilly and Company(USA)
  • AstraZeneca PLC(UK)
  • Sanofi S.A.(France)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Hikma Pharmaceuticals PLC(UK)
  • Lupin Ltd.(India)
  • Recordati S.p.A.(Italy)
  • Xeris Biopharma Holdings, Inc.(USA)
  • Peptron Inc.(South Korea)

결론과 권장사항

KSA 25.02.11

Global Acromegaly Treatment Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.49 billion in 2024 to USD 2.39 billion by 2032, growing at a CAGR of 6.1% during the forecast period (2025-2032).

The acromegaly treatment market is poised for robust growth, driven by the rising incidence of the disease and the increasing demand for innovative therapies. With a surge in research and development investments, pharmaceutical companies are focused on creating new drug formulations and administration methods. The prevalence of hereditary conditions and lifestyle changes is expected to fuel this demand, especially as hormonal disorders become more common. Notably, a strong pharmacological pipeline, including anticipated FDA approvals for new growth hormone receptor antagonists and somatostatin analogues, will further elevate market potential. Technological advancements in detection methods like radiosurgery are set to enhance treatment efficacy and reduce side effects. Additionally, supportive government policies and programs for rare diseases will contribute to market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acromegaly Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acromegaly Treatment Market Segmental Analysis

Global Acromegaly Treatment Market is segmented by Disease Type, Diagnosis Type, Treatment Type and region. Based on Disease Type, the market is segmented into Ectopic Acromegaly and Pseudo Acromegaly. Based on Diagnosis Type, the market is segmented into Medical Imaging and Medical Laboratory Test. Based on Treatment Type, the market is segmented into Surgery, Drug Therapy and Radiation Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acromegaly Treatment Market

The acromegaly treatment market is predominantly driven by the rising incidence of acromegaly, a rare endocrine disorder characterized by an overproduction of growth hormone. As awareness surrounding the condition increases and diagnostic capabilities enhance, more individuals are being identified and treated for acromegaly. This growing recognition of the disease correlates with heightened demand for effective therapeutic solutions, stimulating advancements in treatment options. Consequently, the escalating prevalence of acromegaly significantly propels the market forward, creating opportunities for pharmaceutical companies to innovate and expand their offerings in this specialized healthcare sector as patient needs evolve.

Restraints in the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market faces significant restraints, primarily due to limited awareness and underdiagnosis of the condition. Although acromegaly is becoming more prevalent, many cases remain undetected or are diagnosed later than ideal because the symptoms develop gradually and are often non-specific. This lack of awareness among healthcare professionals and the general public contributes to delays in diagnosis and treatment, ultimately hindering the growth of the market. Addressing these awareness gaps is crucial for facilitating early detection and improving patient outcomes in acromegaly treatment.

Market Trends of the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market is increasingly trending towards targeted therapies, significantly reshaping treatment approaches. This shift is characterized by the rising adoption of somatostatin analogs and growth hormone receptor antagonists, which adeptly address the underlying hormonal imbalances that contribute to acromegaly. By providing enhanced efficacy and improved tolerability compared to traditional treatments, these innovative therapies cater to the growing demand for personalized medicine. As awareness and diagnosis rates of acromegaly rise, coupled with advancements in pharmaceutical research, the market is projected to expand, driven by the continued development and commercialization of these specialized treatment options.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Acromegaly Treatment Market Size by Disease Type & CAGR (2025-2032)

  • Market Overview
  • Ectopic Acromegaly
  • Pseudo Acromegaly

Global Acromegaly Treatment Market Size by Diagnosis Type & CAGR (2025-2032)

  • Market Overview
  • Medical Imaging
  • Medical Laboratory Test

Global Acromegaly Treatment Market Size by Treatment Type & CAGR (2025-2032)

  • Market Overview
  • Surgery
  • Drug Therapy
  • Radiation Therapy

Global Acromegaly Treatment Market Size & CAGR (2025-2032)

  • North America (Disease Type, Diagnosis Type, Treatment Type)
    • US
    • Canada
  • Europe (Disease Type, Diagnosis Type, Treatment Type)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Disease Type, Diagnosis Type, Treatment Type)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Disease Type, Diagnosis Type, Treatment Type)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Disease Type, Diagnosis Type, Treatment Type)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ipsen Pharma (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Crinetics Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Strongbridge Biopharma plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ionis Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hikma Pharmaceuticals PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lupin Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Recordati S.p.A. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Xeris Biopharma Holdings, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Peptron Inc. (South Korea
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제